Fanconi anemia: genes and variants
Explore variant evidence for Fanconi anemia across 11 analyzed proteins (FANCA, FANCD2, FANCC, RAD51C, BRCA2 and 6 more). Linked ClinVar records include 21 pathogenic or likely pathogenic variants, 1,579 variants of uncertain significance and 152 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Counts refer to the selected disease label.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Fanconi anemia
FANCA: Fanconi anemia group A protein
It helps assemble the Fanconi-anemia core complex that monoubiquitinates FANCD2 and FANCI after DNA interstrand crosslinks stall replication. Biallelic loss-of-function variants are the most common cause of Fanconi anemia, with bone-marrow failure and cancer predisposition.
15 ClinVar pathogenic / likely pathogenic and 895 uncertain variants in FANCA have source records linked to Fanconi anemia. Association strength is not clinical gene validity.
FANCD2: Fanconi anemia group D2 protein
Its damage-induced monoubiquitination recruits and coordinates nucleases and homologous-recombination factors at stalled replication forks and interstrand crosslinks. Biallelic loss-of-function variants cause Fanconi anemia group D2.
5 ClinVar pathogenic / likely pathogenic and 476 uncertain variants in FANCD2 have source records linked to Fanconi anemia. Association strength is not clinical gene validity.
FANCC: Fanconi anemia group C protein
It contributes to activation of the FANCD2-FANCI DNA-repair pathway after replication-blocking lesions. Biallelic loss-of-function variants cause Fanconi anemia group C, with chromosome instability, marrow failure, congenital abnormalities, and elevated cancer risk.
1 ClinVar pathogenic / likely pathogenic and 360 uncertain variants in FANCC have source records linked to Fanconi anemia. Association strength is not clinical gene validity.
RAD51C: DNA repair protein RAD51 homolog 3
It participates in RAD51-paralog complexes that promote homologous-recombination repair and restart damaged replication forks. Heterozygous loss-of-function variants increase ovarian and breast-cancer risk, while biallelic variants can cause Fanconi anemia.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in RAD51C have source records linked to Fanconi anemia. Association strength is not clinical gene validity.
BRCA2: Breast cancer type 2 susceptibility protein
It loads RAD51 onto damaged DNA to enable homologous recombination and also protects stressed replication forks from degradation. Germline loss-of-function variants strongly predispose to breast, ovarian, prostate, pancreatic, and other cancers.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in BRCA2 have source records linked to Fanconi anemia. Association strength is not clinical gene validity.
BRIP1: Fanconi anemia group J protein
It unwinds DNA structures and works with BRCA1 and the Fanconi-anemia pathway to repair damaged replication intermediates and interstrand crosslinks. Biallelic loss causes Fanconi anemia group J, while heterozygous loss-of-function variants increase ovarian-cancer risk.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in BRIP1 have source records linked to Fanconi anemia. Association strength is not clinical gene validity.
ERCC4: DNA repair endonuclease XPF
Together with ERCC1, it makes structure-specific DNA incisions required for nucleotide-excision repair and interstrand-crosslink repair. Biallelic pathogenic variants can cause xeroderma pigmentosum, Fanconi anemia, or severe progeroid DNA-repair disease.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in ERCC4 have source records linked to Fanconi anemia. Association strength is not clinical gene validity.
PALB2: Partner and localizer of BRCA2
It physically links BRCA1 and BRCA2 and helps recruit BRCA2-RAD51 repair machinery to DNA double-strand breaks. Heterozygous loss-of-function variants substantially increase breast and pancreatic cancer risk, while biallelic variants cause Fanconi anemia subtype N.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in PALB2 have source records linked to Fanconi anemia. Association strength is not clinical gene validity.
POLG: DNA polymerase subunit gamma-1
It replicates and repairs mitochondrial DNA and is therefore essential for maintaining mitochondrial genome copy number and integrity. Pathogenic variants cause a broad spectrum including Alpers syndrome, progressive external ophthalmoplegia, epilepsy, ataxia, neuropathy, and liver disease.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in POLG have source records linked to Fanconi anemia. Association strength is not clinical gene validity.
RAD51: DNA repair protein RAD51 homolog 1
A DNA-repair recombinase that helps find matching DNA sequences and exchange strands during homologous recombination. This pathway repairs DNA breaks and supports genome stability.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in RAD51 have source records linked to Fanconi anemia. Association strength is not clinical gene validity.
XRCC2: DNA repair protein XRCC2
It acts with other RAD51 paralogs to assemble and stabilize homologous-recombination repair machinery at DNA double-strand breaks. Biallelic loss-of-function variants can cause Fanconi-anemia-like chromosome-instability disease, while heterozygous cancer-risk associations are less certain.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in XRCC2 have source records linked to Fanconi anemia. Association strength is not clinical gene validity.
ClinVar pathogenic and likely pathogenic variants linked to Fanconi anemia
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| FANCA Q436R | 436 | Pathogenic / likely pathogenic (★★) | |
| FANCA P1164S | 1164 | Pathogenic / likely pathogenic (★★) | |
| FANCA R1055Q | 1055 | Pathogenic / likely pathogenic (★★) | |
| FANCA R764W | 764 | Pathogenic / likely pathogenic (★★) | |
| FANCC M1I | 1 | Pathogenic / likely pathogenic (★★) | |
| FANCD2 R302W | 302 | Interaction with BRCA2 | Pathogenic / likely pathogenic (★★) |
| FANCD2 R815Q | 815 | Pathogenic / likely pathogenic (★★) | |
| FANCA H1110P | 1110 | Pathogenic / likely pathogenic (★★) | |
| FANCD2 R1236H | 1236 | Pathogenic / likely pathogenic (★★) | |
| FANCD2 S126G | 126 | Interaction with FANCE | Pathogenic / likely pathogenic (★★) |
| FANCA Q436H | 436 | Pathogenic / likely pathogenic (★) | |
| FANCA P1164L | 1164 | Pathogenic / likely pathogenic (★) | |
| FANCA R435P | 435 | Pathogenic / likely pathogenic (★) | |
| FANCA R1055G | 1055 | Pathogenic / likely pathogenic (★) | |
| FANCA W957G | 957 | Pathogenic / likely pathogenic (★) | |
| FANCA R1117T | 1117 | Pathogenic / likely pathogenic (★) | |
| FANCA T1131N | 1131 | Pathogenic / likely pathogenic (★) | |
| FANCA V1112G | 1112 | Pathogenic / likely pathogenic (★) | |
| FANCA D1429Y | 1429 | Pathogenic / likely pathogenic (★) | |
| FANCD2 L153S | 153 | Interaction with FANCE | Pathogenic / likely pathogenic (★) |
| FANCA Q869E | 869 | Pathogenic / likely pathogenic (★) |
Which prediction tools work for Fanconi anemia
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- MetaSVM: 98 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 98 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- REVEL: 96 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CADD: 94 out of 100
- SIFT: 94 out of 100
- CATVariant: 94 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- AlphaMissense: 91 out of 100
- PolyPhen-2: 91 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- phyloP: 90 out of 100
- MutPred: 87 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SpliceAI: 78 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- ESM1b (LLR): 75 out of 100
- Pangolin: 35 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Same protein, different disease
- Fanconi anemia complementation also has ClinVar records linked to FANCA variants; they fall mostly in different places as the Fanconi anemia variants (38 pathogenic / likely pathogenic).
Diseases related to Fanconi anemia
- Fanconi anemia complementation, also linked to BRCA2, BRIP1, ERCC4, FANCA and 7 more
- Ovarian cancer, also linked to BRCA2, BRIP1, ERCC4, FANCA and 3 more
- Hereditary breast ovarian cancer syndrome, also linked to BRCA2, BRIP1, FANCC, FANCD2 and 2 more
- Acute myeloid leukemia, also linked to ERCC4, FANCA, FANCC, FANCD2 and 1 more
- Hereditary breast cancer, also linked to BRCA2, BRIP1 and PALB2
- Gastric cancer, also linked to BRIP1, PALB2 and RAD51C
- Ovarian neoplasm, also linked to BRCA2 and BRIP1
- Breast and/or ovarian cancer, also linked to BRIP1 and RAD51C
- Familial ovarian cancer, also linked to BRIP1 and RAD51C
- Familial pancreatic carcinoma, also linked to BRCA2 and PALB2
- Hereditary spastic paraplegia, also linked to POLG
- Progressive sclerosing poliodystrophy, also linked to POLG
Frequently asked questions
Which genes have records linked to Fanconi anemia?
This view contains 11 analyzed proteins: FANCA, FANCD2, FANCC, RAD51C, BRCA2 and 6 more. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 21 pathogenic or likely pathogenic variants, 1,579 variants of uncertain significance and 152 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 1,915 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center